a) Schematic example of an umbrella trial.

Slides:

Advertisements

Similar presentations

Precision Medicine: From stratified therapies to personalized therapies Fabrice ANDRE Institut Gustave Roussy Villejuif, France.

Advertisements

© 2005 Prentice Hall Inc. / A Pearson Education Company / Upper Saddle River, New Jersey Lung Cancer and Gefitinib  Lung cancer statistics in the.

Transthoracic needle biopsy of lung adenocarcinoma: all tumour cells are stained with 5A4 clone (anaplastic lymphoma kinase (ALK) immunohistochemistry.

Testing algorithm integrating diagnostic and predictive analysis in nonsmall cell lung cancer (NSCLC). Testing algorithm integrating diagnostic and predictive.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Predictive biomarker analyses in cytological specimens

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Kaplan–Meier survival curves of overall survival (OS) for EGFR mutant lung adenocarcinoma patients who received epidermal growth factor receptor tyrosine.

Flowchart showing the requirement for starting, documenting and evaluating the effect on quality of life (QoL) of interdisciplinary best supportive care.

Familial history of hereditary haemorrhagic telangiectasis (HHT) of the 29-yr-old patient (•) with HHT and severe pulmonary arterial hypertension (PAH).

Detection rate for EGFR mutations in cfDNA.

High-resolution chest computed tomography images of a patient with lymphangioleiomyomatosis, showing round-shaped, thin-walled cysts distributed diffusely.

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Schematic representation of breathing levels during positive expiratory pressure in an obstructed patient. Schematic representation of breathing levels.

a) Chest radiograph showing bilateral coarse interstitial shadowing

Clinical courses of patients.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

a) Schematic example of a basket trial.

Electromagnetic navigation image: the icon representing the locatable guide (arrow) can be seen 3 mm away from the centre of a small pulmonary nodule in.

A) Healthcare utilisation, b) short form (SF)-12 scores and c) work productivity and activity impairment in patients with asthma (▓) and diabetes (▪) in.

Radiodiagnostic imaging

3-year survival of lung cancer patients in the general population and in those with a prior diagnosis of chronic obstructive pulmonary disease (COPD).

Positron emission tomography scan in the axial plane performed in June 2007 showing intense and homogeneous increased uptake of 18-fluorodeoxyglucose within.

Contrast-enhanced computed tomography (CT) of the chest; case two, 4 days after presentation. a) Axial CT image of the upper thorax at the level of the.

A summary of the pathogenesis, pathophysiology and clinical implications of the pulmonary vascular and cardiac abnormalities in interstitial lung disease.

Summary of this study. Summary of this study. Cysteinyl-leukotrienes (cys-LTs) stimulate mitogenesis of bronchial fibroblasts only in the presence of RTK.

Limitations of two-dimensional (2D) measurements.

Effect of omalizumab on change from baseline (B) in a) total asthma symptom score, b) total rhinitis symptom score, and c) combined asthma and rhinitis.

Simplified diagram of the multidisciplinary process to diagnose interstitial lung disease, including a clinician, radiologist, pathologist and also a geneticist:

Morphological subtypes of cyst-related primary lung malignancies

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) for EGFR mutant lung adenocarcinoma.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of studies identified to investigate the role of domestic volatile.

Pulmonary angiography in the right lung (a, c, e and g) and the left lung (b, d, f and h) of a patient with chronic thromboembolic pulmonary hypertension.

Duration of antibiotic therapy according to clinical pulmonary infection score in a randomised trial of an antibiotic discontinuation policy for clinically.

Morbidity and mortality benefits with statin use in observational studies on a logarithmic scale. Morbidity and mortality benefits with statin use in observational.

A) Molecular structure and b) schematic diagram of immunoglobulin (Ig)E. a) Molecular structure and b) schematic diagram of immunoglobulin (Ig)E. The variable.

A–c) Case 1, with epidermal growth factor receptor (EGFR) exon 21 mutations (V843I and L858R). a) Pedigree chart. a–c) Case 1, with epidermal growth factor.

Invasive pulmonary aspergillosis

Schematic diagram of the recently described concept of “systems medicine” [93], which includes genetic characterisation, cell biology and physiology, imaging.

A) Conventional pulmonary angiogram, with b) and c) corresponding optical coherence tomography images from a patient with chronic thromboembolic pulmonary.

Overall forest plot from meta-analysis carried out in 11 studies a) assessing the relative risk of adverse events; and subgroup analysis performed on studies.

Fig. 1 Molecular imaging of EGFR-activating mutation status for stratification of patients. Molecular imaging of EGFR-activating mutation status for stratification.

Schematic diagram of the shared subgroups between asthma and chronic obstructive pulmonary disease (COPD). Schematic diagram of the shared subgroups between.

Forest plot from meta-analysis carried out on four studies including high-dose N-acetylcysteine (NAC) treatment a) assessing the relative risk of chronic.

Correlation between inspiratory capacity (IC)/total lung capacity (TLC) ratio and oxygen pulse at peak exercise in chronic obstructive pulmonary disease.

Forest plot of (left) overall survival and (right) progression-free survival for gefitinib versus docetaxel in the INTEREST (IRESSA NSCLC Trial Evaluating.

Time intervals and corresponding published guidelines in lung cancer care. Time intervals and corresponding published guidelines in lung cancer care. GP:

Risk ratio (RR) and number needed to treat (NNT) are time-dependent measures. a) When an intervention is associated with constant relative risk reduction.

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain and ×10 growth). Bronchial biopsy from patient 5 (a; Haematoxylin-Eosin-Safran stain.

Patient with inoperable chronic thromboembolic pulmonary hypertension showing a typical aspect of subpleural hypoperfusion at the capillary phase of pulmonary.

Pathogenic concepts of pulmonary arterial hypertension (PAH).

Abdominal magnetic resonance imaging of a patient with tuberous sclerosis complex lymphangioleiomyomatosis and multiple small renal angiomyolipomas (arrows)

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

Hyperplastic alveolar epithelial type II cells show severe endoplasmic reticulum stress and consecutive apoptosis. Hyperplastic alveolar epithelial type.

24-h blood pressure profile after a, d) one night of intermittent hypoxia (IH) exposure, b, e) 13 nights IH exposure and c, f) 5 days after cessation of.

Pulmonary artery pressure in a) healthy subjects and b) pulmonary hypertension (PH) subjects. Pulmonary artery pressure in a) healthy subjects and b) pulmonary.

Comparison of primary end-points against guidelines

Trends of mortality rates in the USA between 1930 and 2000 in males according to cancer site. –––––: stomach; ·······: prostate; –– –– ––: colon and rectum;

Comparison of cancer-specific survival in patients with nonsmall cell lung cancer detected incidentally by computed tomography (CT) (n=41) or chest radiography.

Mean change from baseline in percentage predicted forced vital capacity (FVC) in the a) phase III CAPACITY [27] and b) ASCEND [14] studies. #: n=174; ¶:

The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients Gokoulakrichenane Loganadane, MD, Lizza Hendriks, MD, PhD, Cécile.

Volatolomics in cancer

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

High-resolution computed tomography images of smoking-related interstitial lung diseases (ILDs). a) Pulmonary Langerhans cell histiocytosis, b) respiratory.

The natural history of chronic obstructive pulmonary disease (COPD) is a mixture of the natural history of the various phenotypes making up the umbrella.

Presentation transcript:

a) Schematic example of an umbrella trial. a) Schematic example of an umbrella trial. These trials embrace centralised analysis to define the molecular portrait and molecularly selected cohorts with matched drugs [7]. These trials may fall into the “trial to conclude” category. b) Schematic illustration of the SAFIR02_Lung trial (Intergroup Trial UNICANCER UC 0105-1305/IFCT 1301). This is an open-label, multicentric, randomised, phase II trial [11]. NSCLC: nonsmall cell lung cancer; EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; CGH: comparative genomic hybridisation. Images courtesy of Gustave Roussy Cancer Campus Grand Paris, Villejuif, France. Jessica Menis et al. Eur Respir Rev 2014;23:367-378 ©2014 by European Respiratory Society